Mankind Pharma 計劃透過 QIP 籌集 300 億盧比，以償還與 BSV 收購相關的債務

Mankind Pharma Ltd. 宣布計劃透過合格機構配售 (QIP) 籌集近 300 億盧比的股權。透過本次QIP籌集的資金將主要用於償還與收購Bharat Serums and Vaccines (BSV)相關的部分債務

Pharmaceutical company Mankind Pharma Ltd. announced plans to raise nearly ₹3,000 crore through a Qualified Institutional Placement (QIP) of equity shares on Friday.

製藥公司 Mankind Pharma Ltd. 週五宣布計劃透過合格機構配售 (QIP) 籌集近 300 億盧比的資金。

The company’s Fund Raising Committee of Directors approved the allotment of 1.19 crore equity shares at a face value of ₹1 each to eligible Qualified Institutional Buyers (QIBs) in a meeting held on December 20, 2024. The equity shares will be issued at ₹2,520 per share, which includes a premium of ₹2,519 per share, for a total of ₹2,999.99 crore. Following the allotment, Mankind Pharma’s paid-up equity share capital will increase from ₹40.6 crore to ₹41.25 crore, with the same number of equity shares.

該公司的籌款董事會在2024 年12 月20 日舉行的會議上批准向符合條件的合格機構買家(QIB) 配發11.9 億盧比每股面值1 盧比的股票。 。配股完成後，Mankind Pharma 的實收股本將從 4.06 億盧比增至 4.125 億盧比，股本數量不變。

The largest allotment in this issue was made to the Government Pension Fund Global, which acquired 8.33% of the total shares, amounting to 9,92,064 shares.

本期最大配股為Government Pension Fund Global，佔總股本的8.33%，達9,92,064股。

The funds raised through this QIP will primarily be used for the partial repayment of debt related to the acquisition of Bharat Serums and Vaccines (BSV), a major player in the biologics and vaccines sector. Mankind Pharma completed the acquisition of BSV in July for an enterprise value of ₹13,630 crore.

透過本次 QIP 籌集的資金將主要用於償還與收購 Bharat Serums and Vaccines (BSV)（生物製品和疫苗行業的主要參與者）相關的部分債務。 Mankind Pharma 於 7 月完成了對 BSV 的收購，企業價值為 1363 億盧比。

Despite the QIP, Mankind Pharma’s shares saw a 1.97% decline, trading at ₹2,832.55 per share on the Bombay Stock Exchange (BSE) at 12:34 am on December 20.

儘管有 QIP，Mankind Pharma 的股價仍下跌了 1.97%，12 月 20 日凌晨 12:34 在孟買證券交易所 (BSE) 的交易價格為每股 2,832.55 盧比。

In its latest financial results for the quarter ending September 30, 2024, Mankind Pharma reported a 30.4% year-on-year increase in net profit, amounting to ₹653.5 crore, up from ₹501 crore in the same quarter of the previous year. The company also saw a 13.6% rise in revenue from operations, which stood at ₹3,076.5 crore. At the operating level, EBITDA surged by 24.5% to ₹850 crore, compared to ₹682.6 crore in the second quarter of FY24.

Mankind Pharma 在截至 2024 年 9 月 30 日的季度最新財務業績中報告，淨利潤同比增長 30.4%，達到 65.35 億盧比，高於上年同期的 50.1 億盧比。該公司的營運收入也成長了 13.6%，達到 307.65 億盧比。在營運層面，EBITDA 飆升 24.5%，達到 85 億盧比，而 2024 財年第二季為 68.26 億盧比。